FDA approves new treatment for erosive esophagitis
The U.S. Food and Drug Administration (FDA) has approved vonoprazan tablets 10 mg and 20 mg (Voquezna, Phathom Pharmaceuticals) for the cure and maintenance of healing of all grades of erosive esophagitis, also known as erosive gastroesophageal reflux disease (GERD), as well as relief from associated heartburn, the company announced. Vonoprazan, an oral potassium-competitive acid …
